Investigation of the relationship between the Th17/IL-23 pathway and innate-adaptive immune system in TNBS-induced colitis in rats

Document Type : Original Article


1 Namik Kemal University, School of Health, 59030, Tekirdag, Turkey

2 University of Trakya, Faculty of Medicine, Department of Histology- Embryology, Balkan Campus, 22030, Edirne, Turkey


Objective(s): This study was aimed at investigating immune activations of the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model in colonic mucosa by immunohistochemical and Western blot methods.
Materials and Methods: For this purpose, 16 female Wistar albino rats were divided into two random groups of control (n=8) and colitis (n=8). The experimental colitis model was induced by intracolonic administration of TNBS (25 mg/rat). Control animals received only rectal saline for the same time. The animals were sacrificed on the 15th day after TNBS administration, and colon tissue was removed and examined morphologically. Colon samples were stained immunohistochemically with anti-CD3, anti-CD4, anti-CD5, anti-CD8, anti-CD11b, anti-CD45, anti-TNF-α, anti-IL-17, anti-IL-22 and anti-IL-23 antibodies. Additionally, the colonic tissue IL-17 and IL-22 expressions were examined by the Western blot method.
Results: In the experimental results, it was determined that there was a significant decrease in body weight and an increase in colon weight in the colitis group when comparing initial experiments. The colon tissue ulcerations, inflammation, crypt loss and Goblet cell loss were observed in the colitis group in microscopic examinations. The immunohistochemical positive cell numbers significantly increased in the colitis group. The immunoreactive lymphocytes in the propria, intracryptal and submucosal layers were found to be increased in the colitis group of rats. In addition, IL-17 and IL-23 expressions were increased in colitis colon mucosa found by Western blot analysis.
Conclusion: The Th17/IL-23 pathway and IL-22 serve important roles in the pathogenesis of ulcerative colitis, and will be further examined by study.


1. Azuma K, Osaki T, Kurozumi S, Kiyose M, Tsuka T, Murahata Y, et al. Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease. Carbohydr Polym 2015; 115:448-456.
2. Al-Rejaie SS, Abuohashish HM, Al-Enazi MM, Al-Assaf AH, Parmar MY, Ahmed MM. Protective effect of naringenin on acetic acid-induced ulcerative colitis in rats. World J Gastroenterol 2013; 19:5633.
3. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, et al. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-κ Bp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 2006; 2006:92642.
4. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15:199-207.
5. Hongbao M, Young M, Yan Y. Cluster of Differentiation (CD). N Y Sci J 2015; 8:49-53.
6. Zola H, Swart B, Nicholson I, Aasted B, Bensussan A, Boumsell L, et al. CD molecules 2005: human cell differentiation molecules. Blood 2005; 106:3123-3126.
7. Karaca T, Şimşek N, Uslu S, Kalkan Y, Can I, Kara A, et al. The effect of royal jelly on CD3+, CD5+, CD45+ T-cell and CD68+ cell distribution in the colon of rats with acetic acid-induced colitis. Allergol Immunopathol (Madr) 2012; 40:357-361.
8. Műzes G, Molnár B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 2012; 18:5848.
9. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116:1218.
10. Zhu J, Paul WE. Peripheral CD4+ T‐cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010; 238:247-262.
11. Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R, et al. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 2014; 63:943-950.
12. Zhou L, Littman DR. Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol 2009; 21:146-152.
13. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467-476.
14. Fantini M, Monteleone G, MacDonald T. IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunol 2008; 1:110-115.
15. Aujla S, Kolls J. IL-22: a critical mediator in mucosal host defense. J Mol Med (Berl) 2009; 87:451-454.
16. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14:282-289.
17. Seiderer J, Brand S. IL‐22: A two‐headed cytokine in IBD? Inflamm Bowel Dis 2009; 15:473-474.
18. Yamamoto-Furusho JK, Miranda-Pérez E, Fonseca-Camarillo G, Sánchez-Muñoz F, Dominguez-Lopez A, Barreto-Zuniga R. Colonic epithelial upregulation of interleukin 22 (IL‐22) in patients with ulcerative colitis. Inflamm Bowel Dis 2010; 16:1823.
19. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ, Maloy KJ, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 2010; 33:279-288.
20. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, Mckenzie B, et al. IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310-1316.
21. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin-23 drives innate and T cell–mediated intestinal inflammation. J Exp Med 2006; 203:2473-2483.
22. Karaca T, Uz YH, Demirtas S, Karaboga I, Can G. Protective effect of royal jelly in 2, 4, 6 trinitrobenzene sulfonic acid-induced colitis in rats. Iran J Basic Med Sci 2015; 18:370.
23. McCafferty DM, Sharkey KA, Wallace JL. Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol Gastrointest Liver Physiol 1994; 266:G560-G567.
24. Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W. Interferon-gamma (IFN- )-and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999; 116:238-245.
25. Yang M, Lin HB, Gong S, Chen PY, Geng LL, Zeng YM, et al. Effect of Astragalus polysaccharides on expression of TNF-α, IL-1β and NFATc4 in a rat model of experimental colitis. Cytokine 2014; 70:81-86.
26. Kolgazi M, Uslu U, Yuksel M, 0Velioglu-Ogunc A, Ercan F, Alican I. The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat. Chem Biol Interact 2013; 205:72-80.
27. Wakuda T, Azuma K, Saimoto H, Ifuku S, Morimoto M, Arifuku I, et al. Protective effects of galacturonic acid-rich vinegar brewed from Japanese pear in a dextran sodium sulfate-induced acute colitis model. J Funct Foods 2013; 5:516-523.
28. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, Fuss IJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008; 118:545-559.
29. Forster K, Goethel A, Chan CWT, Zanello G, Streutker C, Croitoru K. An oral CD3-specific antibody suppresses T-cell–induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology 2012; 143:1298-1307.
30. Reinecke K, Eminel S, Dierck F, Roessner W, Kersting S, Chromik AM, et al. The JNK inhibitor XG-102 protects against TNBS-induced colitis. Plos One 2012; 7(3): e30985.
31. Dasu T, Qualls JE, Tuna H, Raman C, Cohen DA, Bondada S. CD5 plays an inhibitory role in the suppressive function of murine CD4+ CD25+ T reg cells. Immunol Lett 2008; 119:103-113.
32. Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 1999; 19:2903-2912.
33. Gulubova MV, Manolova IM, Vlaykova TI, Prodanova M, Jovchev JP. Adhesion molecules in chronic ulcerative colitis. Int J Colorectal Dis 2007; 22:581-589.
34. Vainer B, Nielsen OH, Horn T. Comparative studies of the colonic in situ expression of intercellular adhesion molecules (ICAM-1,-2, and-3), β2 integrins (LFA-1, Mac-1, and p150, 95), and PECAM-1 in ulcerative colitis and Crohn's disease. Am J Surg Pathol 2000; 24:1115-1124.
35. Wang L, Jiang X, Liu X, Qian T, Chu Y. Local immune compartments are related to the severity of dextran sodium sulphate induced colitis. Biosci Trends 2014; 8:242-247.
36. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005; 6:873-879.
37. Lu Y, Hong B, Li H, Zheng Y, Zhang M, Wang S, et al. Tumor-specific IL-9–producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci 2014; 111:2265-2270.
38. Chen J, Bruce D, Cantorna MT. Vitamin D receptor expression controls proliferation of naive CD8+ T cells and development of CD8 mediated gastrointestinal inflammation. BMC Immunol 2014; 15:6.
39. Steinhoff U, Brinkmann V, Klemm U, Aichele P, Seiler P, Brandt U, et al. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity 1999; 11:349-358.
40. Ghavidel A, Somi MH, Ebrahimzadeh ZA, Halimi M, Tabrizi A. CD4+ and CD8+ T cell count in colonic mucosa of patients with IBD and IBS. J Am Sci 2013; 9(9s).
41. Funderburg NT, Stubblefield Park SR, Sung HC, Hardy G, Clagett B, Ignatz‐Hoover J, et al. Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013; 140:87-97.
42. Liu D, Zhao H, Zhao N, Lu C, Lu A. Effect of Bawei Xilei powder on CD3, CD4, CD8 T-lymphocytes of rats with ulcerative colitis. Zhongguo Zhong Yao Za Zhi 2008; 33:1301-1304.
43. Saunders A, Johnson P. Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal 2010; 22:339-348.
44. Tobisawa Y, Imai Y, Fukuda M, Kawashima H. Sulfation of colonic mucins by N-acetylglucosamine 6-O-sulfotransferase-2 and its protective function in experimental colitis in mice. J Biol Chem 2010; 285:6750-6760.
45. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480-483.
46. Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, et al. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J Gastroenterol 2007; 13:2166.
47. Zhang M, Qiu X, Zhang H, Yang X, Hong N, Yang Y, et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. Plos One 2014; 9:e109146.
48. Yao J, Wei C, Wang JY, Zhang R, Li YX, Wang L-S. Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice. World J Gastroenterol 2015; 21:6572-6581.
49. He Y, Lin LJ, Zheng CQ, Jin Y, Lin Y. Cytokine expression and the role of Thl7 cells in mice colitis. Hepatogastro-enterology 2012; 59:1809-1813.
50. Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bow Dis 2011; 17:831-848.
51. Rutz S, Eidenschenk C, Ouyang W. IL‐22, not simply a Th17 cytokine. Immunol Rev 2013; 252:116-132.
52. Leung J, Davenport M, Wolff M, Wiens K, Abidi W, Poles M, et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 2014; 7:124-133.
53. Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, et al. Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis. World J Gastroenterol 2013; 19:2638-2649.
54. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. Trends Immunol 2006; 27:17-23.
55. Liu Z, Yadav PK, Xu X, Su J, Chen C, Tang M, et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity.  J Leukoc Biol 2011; 89:597–606.